BR112012012767A2 - método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método - Google Patents

método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método

Info

Publication number
BR112012012767A2
BR112012012767A2 BR112012012767A BR112012012767A BR112012012767A2 BR 112012012767 A2 BR112012012767 A2 BR 112012012767A2 BR 112012012767 A BR112012012767 A BR 112012012767A BR 112012012767 A BR112012012767 A BR 112012012767A BR 112012012767 A2 BR112012012767 A2 BR 112012012767A2
Authority
BR
Brazil
Prior art keywords
dry eye
agent
conjunctive
corneal
injury
Prior art date
Application number
BR112012012767A
Other languages
English (en)
Inventor
Akio Siranita
Yukihiko Mashima
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of BR112012012767A2 publication Critical patent/BR112012012767A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/162—Conjunctival disorders, e.g. conjunctivitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método. a presente invenção fornece um método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva de nível de severidade de olho seco 3 ou mais de acordo com o relato do international dry eye workshop (dews report) (2007) e uma composição farmacêutica compreendendo o agente. a presente invenção também fornece um método para o tratamento de olho seco e/ou lesão corneana e conjutiva de nível de severidade de olho seco 3 ou mais de acordo com dews report (2007) usando o agente.
BR112012012767A 2009-11-27 2010-11-26 método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método BR112012012767A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009270356 2009-11-27
PCT/JP2010/071114 WO2011065475A1 (ja) 2009-11-27 2010-11-26 ドライアイおよび/または角結膜障害に対する処置に有効な薬剤のスクリーニング方法および該方法によって得られた医薬組成物

Publications (1)

Publication Number Publication Date
BR112012012767A2 true BR112012012767A2 (pt) 2016-09-06

Family

ID=44066579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012767A BR112012012767A2 (pt) 2009-11-27 2010-11-26 método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método

Country Status (13)

Country Link
US (2) US8871995B2 (pt)
EP (1) EP2506008A4 (pt)
JP (2) JP5809979B2 (pt)
KR (1) KR20120096555A (pt)
CN (1) CN102695954A (pt)
AU (1) AU2010323566B2 (pt)
BR (1) BR112012012767A2 (pt)
CA (1) CA2780650A1 (pt)
MX (1) MX2012006081A (pt)
NZ (2) NZ622403A (pt)
RU (1) RU2564912C2 (pt)
TW (2) TW201526909A (pt)
WO (1) WO2011065475A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005186A1 (en) * 2013-06-27 2015-01-01 Jing-Feng Huang Methods and devices for classifying and managing autoimmune and inflammatory conditions
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
DE102016224679A1 (de) 2016-12-12 2018-06-14 Skf Lubrication Systems Germany Gmbh Schmiermittelapplikator
RU2706715C1 (ru) * 2019-07-10 2019-11-20 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Применение раствора оксиэтиламмония метилфеноксиацетата

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
JPH06271478A (ja) * 1993-03-23 1994-09-27 Otsuka Pharmaceut Co Ltd ドライアイ治療剤
CN1170364A (zh) * 1994-12-19 1998-01-14 大正制药株式会社 脂质体滴眼液
CN1124158C (zh) * 1996-04-19 2003-10-15 株式会社·R-技术上野 含白蛋白为有效成分的药物组合物
TW470648B (en) * 1996-04-19 2002-01-01 R Tech Ueno Ltd A pharmaceutical composition containing albumin as an active ingredient for treating cornea disorder and dry eyes
JP3945625B2 (ja) * 2001-03-30 2007-07-18 株式会社イーエムアイ 角膜上皮障害モデル動物及びそのモデル動物を用いた薬剤の評価方法並びにその評価方法を用いて選択された薬剤
RU2239436C1 (ru) * 2003-07-23 2004-11-10 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Средство для лечения синдрома сухого глаза как осложнения перенесенных офтальмоинфекций
JP4778262B2 (ja) * 2005-04-27 2011-09-21 テイカ製薬株式会社 角膜疾患治療剤
EP2461809A4 (en) * 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
CA2795720A1 (en) * 2010-04-12 2011-10-20 R-Tech Ueno, Ltd. Pharmaceutical composition for treating macular edema
US20120087864A1 (en) * 2010-04-12 2012-04-12 R-Tech Ueno, Ltd. Method for diagnosing and/or evaluating retinal disease

Also Published As

Publication number Publication date
TW201526909A (zh) 2015-07-16
NZ600040A (en) 2014-03-28
EP2506008A4 (en) 2013-05-01
NZ622403A (en) 2015-09-25
CA2780650A1 (en) 2011-06-03
MX2012006081A (es) 2012-06-27
CN102695954A (zh) 2012-09-26
US20150011475A1 (en) 2015-01-08
AU2010323566A1 (en) 2012-06-07
JPWO2011065475A1 (ja) 2013-04-18
RU2564912C2 (ru) 2015-10-10
EP2506008A1 (en) 2012-10-03
JP5809979B2 (ja) 2015-11-11
US9205154B2 (en) 2015-12-08
RU2012126633A (ru) 2014-01-20
KR20120096555A (ko) 2012-08-30
JP2016000757A (ja) 2016-01-07
US8871995B2 (en) 2014-10-28
US20120245090A1 (en) 2012-09-27
WO2011065475A1 (ja) 2011-06-03
TWI508738B (zh) 2015-11-21
AU2010323566B2 (en) 2014-06-05
TW201129376A (en) 2011-09-01

Similar Documents

Publication Publication Date Title
BR112018004620A2 (pt) moduladores da expressão de kras
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112018006445A2 (pt) métodos para tratar distrofia muscular
CU20190045A7 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas que son inhibidores de la dihidroorotato deshidrogenasa (dhodh) útiles para el tratamiento o prevención de trastornos hiperproliferativos e inflamatorios
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2020000383A1 (es) Composiciones de aminoácidos para el tratamiento de lesión neuronal.
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
CO2021015264A2 (es) Inhibidores de dihidroorotato deshidrogenasa
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
ECSP078020A (es) Composición para el tratamiento preventivo del polvo
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
BR112015026660A2 (pt) ligas metálicas aperfeiçoadas para dispositivos médicos
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
BR112016007435A2 (pt) processo para produzir carga tratada, carga tratada, composição de borracha, processo para produzir sílica precipitada tratada e sílica precipitada tratada
BR112012025390A2 (pt) composto de tetraidrobenzotiofeno
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
MX2016007658A (es) Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl.
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013027789A2 (pt) processo para produzir misturas de borracha
BR112012012767A2 (pt) método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método
GT201400242A (es) "nuevos compuestos de pirazol"
BR112017008553A2 (pt) processo de extrusão para polipropileno

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]